218 related articles for article (PubMed ID: 32728528)
21. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Liang J; Li M; Sui Q; Hu Z; Bian Y; Huang Y; Zhan C; Jiang W; Wang Q; Tan L
Transl Lung Cancer Res; 2020 Aug; 9(4):1302-1323. PubMed ID: 32953506
[TBL] [Abstract][Full Text] [Related]
22. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
Stenehjem D; Lubinga SJ; Wu A; Betts KA
J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
[No Abstract] [Full Text] [Related]
23. Immunotherapy in non-small cell lung cancer: Update and new insights.
Mielgo-Rubio X; Uribelarrea EA; Cortés LQ; Moyano MS
J Clin Transl Res; 2021 Feb; 7(1):1-21. PubMed ID: 34104805
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
[TBL] [Abstract][Full Text] [Related]
25. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
26. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
27. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
28. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
31. Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances.
Dehghani T; Shahrjerdi A; Kahrizi MS; Soleimani E; Ravandeh S; Merza MS; Rahnama N; Ebrahimzadeh F; Bakhshesh M
Pathol Res Pract; 2023 Jun; 246():154470. PubMed ID: 37150133
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
33. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
34. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Leal TA; Ramalingam SS
J Thorac Dis; 2018 Feb; 10(Suppl 3):S422-S432. PubMed ID: 29593888
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
38. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
39. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
40. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
Pabani A; Butts CA
Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
